Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neuronetics Inc
(NQ:
STIM
)
3.555
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neuronetics Inc
< Previous
1
2
Next >
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
May 01, 2024
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance
From
Neuronetics
Via
GlobeNewswire
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
April 10, 2024
Lack of early symptom improvement is not predictive of final responder status
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
March 25, 2024
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
March 07, 2024
From
Neuronetics
Via
GlobeNewswire
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
February 12, 2024
Advancements provide workflow efficiencies for NeuroStar® TMS providers
From
Neuronetics
Via
GlobeNewswire
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
February 06, 2024
Criteria Change Reduces Requirements for Treatment Accessibility
From
Neuronetics
Via
GlobeNewswire
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
December 18, 2023
New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers
From
Neuronetics
Via
GlobeNewswire
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
December 04, 2023
Technological advances reduce time and increase efficiency for MDD treatment
From
Neuronetics
Via
GlobeNewswire
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
November 13, 2023
New updates designed to advance practice efficiency and patient outcomes
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
November 09, 2023
Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives
From
Neuronetics
Via
GlobeNewswire
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
October 16, 2023
Findings confirm strong correlation between the number of TMS treatment sessions completed and improvement in MDD
From
Neuronetics
Via
GlobeNewswire
In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression
September 12, 2023
Portal provides resources to raise awareness around mental health and suicide prevention
From
Neuronetics
Via
GlobeNewswire
NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
August 21, 2023
Award Acknowledges Excellence in Digital Marketing Efforts
From
Neuronetics
Via
GlobeNewswire
Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
August 14, 2023
New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans
July 19, 2023
Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives
From
Neuronetics
Via
GlobeNewswire
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
July 11, 2023
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment
From
Neuronetics
Via
GlobeNewswire
NeuroStar Achieves Milestone Regulatory Clearance in South Korea
July 17, 2023
First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ Technologies
From
Neuronetics
Via
GlobeNewswire
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
June 12, 2023
The Company expands technology for patients with obsessive-compulsive disorder
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
May 26, 2023
Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner
From
Neuronetics
Via
GlobeNewswire
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
May 23, 2023
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy
From
Neuronetics
Via
GlobeNewswire
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
May 15, 2023
The Company is recognized for its commitment to employees’ well-being
From
Neuronetics
Via
GlobeNewswire
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
May 08, 2023
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products
From
Neuronetics
Via
GlobeNewswire
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
May 03, 2023
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
May 02, 2023
Campaign features patients’ experiences to support others with depression
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
May 01, 2023
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Expanded TMS Access through United HealthCare
April 28, 2023
UHC Medicare Advantage plans in NGS states expand access via NPPs
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
April 13, 2023
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
April 06, 2023
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
March 16, 2023
Award recognizes NeuroStar for its significant contributions toward patient wellbeing
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
March 02, 2023
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients
From
Neuronetics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.